Cellular prion protein as a receptor for amyloid-β oligomers in Alzheimer's disease

Biochemical and Biophysical Research Communications

Volumn 483, Issue 4, 2017, Pages 1143-1147

  Salazar, Santiago V ^a   Strittmatter, Stephen M ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer's disease; Cellular prion protein

Indexed keywords

AMYLOID BETA PROTEIN; OLIGOMER; PRION PROTEIN; PROTEIN BINDING;

ALZHEIMER DISEASE; DOWNSTREAM PROCESSING; HUMAN; NERVE CELL; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SURFACE PROPERTY; ANIMAL; METABOLISM; MOUSE;

AMYLOID BETA-PEPTIDES; ANIMALS; HUMANS; MICE; PROTEIN BINDING; PRPC PROTEINS; SIGNAL TRANSDUCTION;

EID: 84994406852     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2016.09.062     Document Type: Review

References (34)

1. [1] Alzheimer's, A., Alzheimer's disease facts and figures. Alzheimer's Dement. J. Alzheimer's Assoc. 8 (2012), 131–168.
2. [2] Braak, H., Braak, E., Neuropathological stageing of Alzheimer-related changes. Acta neuropathol. 82 (1991), 239–259.
3. [3] Selkoe, D.J., Alzheimer's disease. Cold Spring Harb. Perspect. Biol., 3, 2011.
4. [4] Benilova, I., Karran, E., De Strooper, B., The toxic Abeta oligomer and Alzheimer's disease: an emperor in need of clothes. Nat. Neurosci. 15 (2012), 349–357.
5. [5] Hardy, J., Selkoe, D.J., The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297 (2002), 353–356.
6. [6] Sheng, M., Sabatini, B.L., Sudhof, T.C., Synapses and Alzheimer's disease. Cold Spring Harb. Perspect. Biol., 4, 2012.
7. [7] Lauren, J., Gimbel, D.A., Nygaard, H.B., Gilbert, J.W., Strittmatter, S.M., Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. Nature 457 (2009), 1128–1132.
8. [8] Gimbel, D.A., Nygaard, H.B., Coffey, E.E., Gunther, E.C., Lauren, J., Gimbel, Z.A., Strittmatter, S.M., Memory impairment in transgenic Alzheimer mice requires cellular prion protein. J. Neurosci. 30 (2010), 6367–6374.
9. [9] Um, J.W., Nygaard, H.B., Heiss, J.K., Kostylev, M.A., Stagi, M., Vortmeyer, A., Wisniewski, T., Gunther, E.C., Strittmatter, S.M., Alzheimer amyloid-beta oligomer bound to postsynaptic prion protein activates Fyn to impair neurons. Nat. Neurosci. 15 (2012), 1227–1235.
10. [10] Um, J.W., Kaufman, A.C., Kostylev, M., Heiss, J.K., Stagi, M., Takahashi, H., Kerrisk, M.E., Vortmeyer, A., Wisniewski, T., Koleske, A.J., Gunther, E.C., Nygaard, H.B., Strittmatter, S.M., Metabotropic glutamate receptor 5 is a coreceptor for Alzheimer abeta oligomer bound to cellular prion protein. Neuron 79 (2013), 887–902.
11. [11] Heiss, J.K., Barrett, J., Yu, Z., Haas, L.T., Kostylev, M.A., Strittmatter, S.M., Early activation of experience-independent dendritic spine turnover in a mouse model of Alzheimer's disease. Cereb. Cortex, 2016 Jun 29 [Epub ahead of print].
12. [12] Haas, L.T., Salazar, S.V., Kostylev, M.A., Um, J.W., Kaufman, A.C., Strittmatter, S.M., Metabotropic glutamate receptor 5 couples cellular prion protein to intracellular signalling in Alzheimer's disease. Brain J. Neurol. 139 (2016), 526–546.
13. [13] Chen, S., Yadav, S.P., Surewicz, W.K., Interaction between human prion protein and amyloid-beta (Abeta) oligomers: role OF N-terminal residues. J. Biol. Chem. 285 (2010), 26377–26383.
14. [14] Dohler, F., Sepulveda-Falla, D., Krasemann, S., Altmeppen, H., Schluter, H., Hildebrand, D., Zerr, I., Matschke, J., Glatzel, M., High molecular mass assemblies of amyloid-beta oligomers bind prion protein in patients with Alzheimer's disease. Brain J. Neurol. 137 (2014), 873–886.
15. [15] Kessels, H.W., Nguyen, L.N., Nabavi, S., Malinow, R., The prion protein as a receptor for amyloid-beta. Nature 466 (2010), E3–E4 discussion E4–5.
16. [16] Balducci, C., Beeg, M., Stravalaci, M., Bastone, A., Sclip, A., Biasini, E., Tapella, L., Colombo, L., Manzoni, C., Borsello, T., Chiesa, R., Gobbi, M., Salmona, M., Forloni, G., Synthetic amyloid-beta oligomers impair long-term memory independently of cellular prion protein. Proc. Natl. Acad. Sci. U. S. A. 107 (2010), 2295–2300.
17. [17] Calella, A.M., Farinelli, M., Nuvolone, M., Mirante, O., Moos, R., Falsig, J., Mansuy, I.M., Aguzzi, A., Prion protein and Abeta-related synaptic toxicity impairment. EMBO Mol. Med. 2 (2010), 306–314.
18. [18] Barry, A.E., Klyubin, I., Mc Donald, J.M., Mably, A.J., Farrell, M.A., Scott, M., Walsh, D.M., Rowan, M.J., Alzheimer's disease brain-derived amyloid-beta-mediated inhibition of LTP in vivo is prevented by immunotargeting cellular prion protein. J. Neurosci. 31 (2011), 7259–7263.
19. [19] Freir, D.B., Nicoll, A.J., Klyubin, I., Panico, S., Mc Donald, J.M., Risse, E., Asante, E.A., Farrow, M.A., Sessions, R.B., Saibil, H.R., Clarke, A.R., Rowan, M.J., Walsh, D.M., Collinge, J., Interaction between prion protein and toxic amyloid beta assemblies can be therapeutically targeted at multiple sites. Nat. Commun., 2, 2011, 336.
20. [20] Klyubin, I., Nicoll, A.J., Khalili-Shirazi, A., Farmer, M., Canning, S., Mably, A., Linehan, J., Brown, A., Wakeling, M., Brandner, S., Walsh, D.M., Rowan, M.J., Collinge, J., Peripheral administration of a humanized anti-PrP antibody blocks Alzheimer's disease Abeta synaptotoxicity. J. Neurosci. 34 (2014), 6140–6145.
21. [21] Kostylev, M.A., Kaufman, A.C., Nygaard, H.B., Patel, P., Haas, L.T., Gunther, E.C., Vortmeyer, A., Strittmatter, S.M., Prion-Protein-interacting amyloid-beta oligomers of high molecular weight are tightly correlated with memory impairment in multiple Alzheimer mouse models. J. Biol. Chem. 290 (2015), 17415–17438.
22. [22] Hu, N.W., Nicoll, A.J., Zhang, D., Mably, A.J., O'Malley, T., Purro, S.A., Terry, C., Collinge, J., Walsh, D.M., Rowan, M.J., mGlu5 receptors and cellular prion protein mediate amyloid-beta-facilitated synaptic long-term depression in vivo. Nat. Commun., 5, 2014, 3374.
23. [23] Haas, L.T., Salazar, S.V., Kostylev, M.A., Um, J.W., Kaufman, A.C., Strittmatter, S.M., Metabotropic glutamate receptor 5 couples cellular prion protein to intracellular signalling in Alzheimer's disease. Brain 139 (2016), 526–546.
24. [24] Larson, M., Sherman, M.A., Amar, F., Nuvolone, M., Schneider, J.A., Bennett, D.A., Aguzzi, A., Lesne, S.E., The complex PrP(c)-Fyn couples human oligomeric Abeta with pathological tau changes in Alzheimer's disease. J. Neurosci. 32 (2012), 16857–16871a.
25. [25] Kaufman, A.C., Salazar, S.V., Haas, L.T., Yang, J., Kostylev, M.A., Jeng, A.T., Robinson, S.A., Gunther, E.C., van Dyck, C.H., Nygaard, H.B., Strittmatter, S.M., Fyn inhibition rescues established memory and synapse loss in Alzheimer mice. Ann. Neurol. 77 (2015), 953–971.
26. [26] Huang, Y., Lu, W., Ali, D.W., Pelkey, K.A., Pitcher, G.M., Lu, Y.M., Aoto, H., Roder, J.C., Sasaki, T., Salter, M.W., MacDonald, J.F., CAKbeta/Pyk2 kinase is a signaling link for induction of long-term potentiation in CA1 hippocampus. Neuron 29 (2001), 485–496.
27. [27] Roselli, F., Hutzler, P., Wegerich, Y., Livrea, P., Almeida, O.F., Disassembly of shank and homer synaptic clusters is driven by soluble beta-amyloid(1-40) through divergent NMDAR-dependent signalling pathways. PloS one, 4, 2009, e6011.
28. [28] Ma, T., Chen, Y., Vingtdeux, V., Zhao, H., Viollet, B., Marambaud, P., Klann, E., Inhibition of AMP-activated protein kinase signaling alleviates impairments in hippocampal synaptic plasticity induced by amyloid beta. J. Neurosci. 34 (2014), 12230–12238.
29. [29] Raka, F., Di Sebastiano, A.R., Kulhawy, S.C., Ribeiro, F.M., Godin, C.M., Caetano, F.A., Angers, S., Ferguson, S.S., Ca(2+)/Calmodulin-dependent protein Kinase II interacts with group I Metabotropic glutamate and facilitates receptor endocytosis and ERK1/2 signaling: role of beta-Amyloid. Mol. Brain, 8, 2015, 21.
30. [30] Kim, T., et al. Human LilrB2 is a beta-amyloid receptor and its murine homolog PirB regulates synaptic plasticity in an Alzheimer's model. Science 341:6152 (2013), 1399–1404.
31. [31] Izzo, N.J., et al. Alzheimer's therapeutics targeting amyloid beta 1-42 oligomers II: Sigma-2/PGRMC1 receptors mediate Abeta 42 oligomer binding and synaptotoxicity. PLoS One, 9(11), 2014 e111899.
32. [32] Izzo, N.J., et al. Alzheimer's therapeutics targeting amyloid beta 1-42 oligomers I: Abeta 42 oligomer binding to specific neuronal receptors is displaced by drug candidates that improve cognitive deficits. PloS One, 9(11), 2014 e111898.
33. [33] Haas, L.T., Strittmatter, S.M., Targeting Aβ receptors to modify Alzheimer's disease progression. Wolfe, M.S., (eds.) Developing Therapeutics for Alzheimer's Disease Progress and Challenges, 2016, Academic Press, 227–250.
34. [34] Smith, L.M., Strittmatter, S.M., Binding site for amyloid-β oligomers and synaptic toxicity. Cold Spring Harb. Perspect. Med., 2016 (in press).